4.43

1.56% -0.07

scPharmaceuticals Inc (SCPH)

Overview News Price History Option Chain Discussions Forecast

scPharmaceuticals Inc stock is currently priced at $4.43, with a 24-hour trading volume of 24,914. It has seen a -1.56% decreased in the last 24 hours and a -8.85% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $4.58 pivot point. If it approaches the $4.41 support level, significant changes may occur.

Previous Close:

$4.50

Open:

$4.47

24h Volume:

24,914

Market Cap:

$162.24M

Revenue:

Net Income/Loss:

$-54.81M

P/E Ratio:

-3.3308

EPS:

-1.33

Net Cash Flow:

$-59.28M

1W Performance:

-1.77%

1M Performance:

-8.85%

6M Performance:

-24.14%

1Y Performance:

-53.32%

1D Range:

$4.33

$4.55

52W Range:

$4.25

$12.75

scPharmaceuticals Inc Stock (SCPH) Company Profile

Name

scPharmaceuticals Inc

Sector

Healthcare (1201)

Industry

Biotechnology (688)

Phone

617-517-0730

Address

2400 District Avenue, Suite 310, Burlington, MA

Employee

Twitter

@scPharmaUSA

Next Earnings Date

2024-05-08

Latest SEC Filings

SCPH's Discussions on Twitter

scPharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-01-22	Initiated	Cowen	Outperform
Oct-21-22	Resumed	Jefferies	Buy
Oct-11-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Aug-02-22	Initiated	Maxim Group	Buy
Sep-09-21	Initiated	SVB Leerink	Mkt Perform
Oct-15-19	Initiated	H.C. Wainwright	Buy
Jan-30-19	Downgrade	Leerink Partners	Outperform → Mkt Perform

View All

scPharmaceuticals Inc Stock (SCPH) Latest News

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

GlobeNewswire Inc.

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

GlobeNewswire Inc.

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

GlobeNewswire Inc.

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

GlobeNewswire Inc.

scPharmaceuticals Inc Stock (SCPH) Financials Data

scPharmaceuticals Inc (SCPH) Net Income 2024

SCPH net income (TTM) was -$54.81 million for the quarter ending December 31, 2023, a -48.79% decrease year-over-year.

scPharmaceuticals Inc (SCPH) Cash Flow 2024

SCPH recorded a free cash flow (TTM) of -$59.28 million for the quarter ending December 31, 2023, a -71.35% decrease year-over-year.

scPharmaceuticals Inc (SCPH) Earnings per Share 2024

SCPH earnings per share (TTM) was -$1.42 for the quarter ending December 31, 2023, a -9.23% decline year-over-year.

scPharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting. Its product pipeline also includes scFurosemide, a loop diuretic for the management of edema in patients with decompensated heart failure; scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.